Antimalarial activity of sera from subjects taking HIV protease inhibitors.
Synergy between HIV and malaria is being increasingly recognized. We examined the antimalarial activity of sera from subjects receiving chloroquine, no drugs or HAART. Sera from subjects taking ritonavir-boosted saquinavir or lopinavir significantly inhibited parasite growth (median of 55 and 69% inhibition, respectively). These results indicate that patients on protease inhibitors may be afforded some protection from malaria. The clinical relevance of these observations will require confirmation in controlled studies in malaria-endemic regions.
Redmond
Andrew M
AM
Department of Infectious Diseases, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
Skinner-Adams
Tina
T
Andrews
Katherine T
KT
Gardiner
Donald L
DL
Ray
John
J
Kelly
Mark
M
McCarthy
James S
JS
D000818:Animals; D000962:Antimalarials / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods; D002738:Chloroquine / Q000627:therapeutic use; D004357:Drug Synergism; D015658:HIV Infections / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D006801:Humans; D061466:Lopinavir; D016778:Malaria, Falciparum / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D010963:Plasmodium falciparum / Q000187:drug effects / Q000254:growth & development; D011744:Pyrimidinones / Q000627:therapeutic use; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D019438:Ritonavir / Q000627:therapeutic use; D019258:Saquinavir / Q000627:therapeutic use; D016896:Treatment Outcome
D000962:Antimalarials; D017320:HIV Protease Inhibitors; D011744:Pyrimidinones; D018894:Reverse Transcriptase Inhibitors; D061466:Lopinavir; D002738:Chloroquine; D019258:Saquinavir; D019438:Ritonavir